Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 5/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | ACE | P12821 | 2/20 | 0.40 |
| ▸ | MME | P08473 | 1/20 | 0.40 |
| ▸ | CPA1 | P15085 | 1/20 | 0.40 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
| ▸ | SI | P14410 | 1/20 | 0.36 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38660142 | 1.00 | MAPT (0.63) | MAPTALDH1A1LMNAPTGS2TDP1 | |
| SCHEMBL20817281 | 0.87 | MAPT (0.63) | MAPTALDH1A1LMNAPTGS2TDP1 | |
| SCHEMBL18850615 | 0.83 | LMNA (0.59) | MAPTALDH1A1LMNAPTGS2TDP1 | |
| SCHEMBL13295878 | 0.82 | TET2 (0.52) | MAPTALDH1A1LMNAPTGS2TDP1 | |
| SCHEMBL9586493 | 0.82 | ALDH1A1 (0.57) | MAPTALDH1A1LMNAPTGS2TDP1 | |
| SCHEMBL18556352 | 0.82 | ALDH1A1 (0.57) | MAPTALDH1A1LMNAPTGS2TDP1 | |
| SCHEMBL10703854 | 0.82 | ALDH1A1 (0.57) | MAPTALDH1A1LMNAPTGS2TDP1 | |
| SCHEMBL29037228 | 0.80 | MEN1 (0.50) | MAPTALDH1A1LMNAPTGS2TDP1 | |
| SCHEMBL24622186 | 0.79 | MME (0.42) | MAPTALDH1A1LMNAPTGS2TDP1 | |
| SCHEMBL13707384 | 0.78 | TET2 (0.48) | MAPTALDH1A1LMNAPTGS2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122059859-A | Synthesis method of diaryl methyl sulfide under biocompatible condition | 南京工业大学 | 2026-05-19 | — | — | CN | disclosed |
| EP-3201168-B1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF MULTIPLE SCLEROSIS | CELLIX BIO PRIVATE LTD (IN) | 2020-03-18 | — | — | EP | disclosed |
| US-9580383-B2 | Compositions and methods for the treatment of multiple sclerosis | CELLIX BIO PRIVATE LIMITED (IN) | 2017-02-28 | — | — | US | disclosed |
| US-9498461-B2 | Compositions and methods for the treatment of inflammatory bowel disease | CELLIX BIO PRIVATE LIMITED (IN) | 2016-11-22 | — | — | US | disclosed |
| US-20160152553-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS | CELLIX BIO PRIVATE LIMITED (IN) | 2016-06-02 | — | — | US | disclosed |
| US-9333187-B1 | Compositions and methods for the treatment of inflammatory bowel disease | CELLIX BIO PRIVATE LIMITED (IN) | 2016-05-10 | — | — | US | disclosed |
| US-20160120838-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | CELLIX BIO PRIVATE LIMITED (IN) | 2016-05-05 | — | — | US | disclosed |
| US-20160120839-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | CELLIX BIO PRIVATE LIMITED (IN) | 2016-05-05 | — | — | US | disclosed |
| US-20160122291-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS | CELLIX BIO PRIVATE LIMITED (IN) | 2016-05-05 | — | — | US | disclosed |
| US-20160090350-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS | CELLIX BIO PRIVATE LIMITED (IN) | 2016-03-31 | — | — | US | disclosed |
| US-9227974-B2 | Compositions and methods for the treatment of respiratory disorders | CELLEX BIO PRIVATE LIMITED (IN) | 2016-01-05 | — | — | US | disclosed |
| US-9102649-B1 | Compositions and methods for the treatment of multiple sclerosis | CELLIX BIO PRIVATE LIMITED (IN) | 2015-08-11 | — | — | US | disclosed |
| US-20150133407-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY DISORDERS | CELLIX BIO PRIVATE LIMITED (IN) | 2015-05-14 | — | — | US | disclosed |
| WO-2012058269-A2 | METHODS OF TREATING CANCER AND OTHER DISEASES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160120838-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | ALPI, SLC10A2, SI | MAPT 431/4885ALDH1A1 934/4885LMNA 4643/4885 |
| US-20160152553-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS | HLA-DRB1, SI, PMP22 | MAPT 157/4885ALDH1A1 2962/4885LMNA 3035/4885 |
| US-20160122291-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS | PMP22, SI, AQP4 | MAPT 58/4885ALDH1A1 2620/4885LMNA 3042/4885 |
| US-20160090350-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS | PMP22, SI, AQP4 | MAPT 52/4885ALDH1A1 3211/4885LMNA 2380/4885 |
| US-20160120839-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | ALPI, SLC10A2, SI | MAPT 431/4885ALDH1A1 934/4885LMNA 4643/4885 |
| US-20150133407-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY DISORDERS | SORD, MUC1, CFTR | MAPT 1246/4885ALDH1A1 1524/4885LMNA 3804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.